FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...

Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...

Cutting Edge Information Analyzes the Bristol-Myers Squibb / Otsuka Pharma Profit-Sharing Strategy for 2010 and Beyond RESEARCH TRIANGLE PARK, NC--(Marketwire - April 16, 2009) - The recently announced deal between Bristol-Myers Squibb and Otsuka over Abilify will go a long way toward shoring up both companies'...

SGLT2 Inhibitors a Promising New Therapy for Type II Diabetes: New Cutting Edge Information Report Analyzes Diabetes Market Forecast Through 2013 RESEARCH TRIANGLE PARK, NC--(Marketwire - December 12, 2008) - A new drug class is poised to make a splash in the diabetes market, according to a new report, "Diabetes Market Forecast to...